Navigation Links
Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
Date:3/26/2009

PRINCETON, N.J., March 26 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, has accepted an invitation to present at the Future Leaders in the Biotech Industry conference in New York. Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will take place on Thursday, April 2, 2009 at 4:00PM EDT in Room 411 of the Millennium Broadway Hotel & Conference Center.

Presenting companies are chosen by BioCentury based on rigorous selection criteria, including investor validation and upcoming milestones, informed by the collective intelligence of Thomson Reuters and the sponsors of the conference.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
3. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
4. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... , ... Eating Recovery Center (ERC), a trusted provider of comprehensive ... Binge Eating Recovery Advocate. An inspiring author and motivational speaker, she will join ERC’s ... speak at and attend various conferences and events throughout the year. ...
(Date:3/1/2017)... Herndon, VA (PRWEB) , ... March 01, 2017 , ... ... on March 5, 2017 by raising awareness of the profession of industrial design ... its website—with robust content geared toward high school students and counselors; parents; and the ...
(Date:3/1/2017)... ... March 01, 2017 , ... On January 27, 2017, ... filed a civil sex abuse lawsuit in the Circuit Court of Kanawha County, West ... only been identified by their initials. See L.B. and T.B. v. Seventh-Day Adventist Church ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living ... mobile app Time & Go. , Time & Go app is the ultimate strategic ... and well-being. Efficient time management methods enable people to work smarter, not harder, that's ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... pricing in the month of March for treatments aimed at tightening skin and ... use on Thermage skin tightening, with 30 percent off all Thermage face and ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... BRENTWOOD, Tenn. , March 1, 2017  Numotion, ... has announced the availability of Tek RMD ("robotic mobilization ... States . Tek RMD is a motorized standing ... are in a manual wheelchair to complete everyday activities ... board and control a Tek RMD unassisted. Numotion is ...
(Date:3/1/2017)... ... Research and Markets has announced the addition of the ... The Global Infertility Therapy Partnering Terms and Agreements ... agreements entered into by the world,s leading healthcare companies. ... deals are discovery or development stage whereby the licensee obtains a ...
(Date:3/1/2017)... MUMBAI, India and PRINCETON, ... Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, ... its subsidiaries or associate companies) today announced that ... Phase-3 clinical trials (reSURFACE 1 and 2) of ... the treatment of moderate-to-severe plaque psoriasis, will be ...
Breaking Medicine Technology: